ZEB1 induces resistance to epirubicin in breast cancer [104], oxaliplatin in esophageal cancer [105], docetaxel in prostate cancer [106], and gemcitabine in pancreatic cancer [107]. This evidence concerns the gene ZEB1 and prostate carcinoma.